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Abstract
Background: Pulmonary arterial hypertension (PAH) is a lethal disease with pronounced narrowing of pulmonary
vessels due to abnormal cell proliferation. The platelet-derived growth factor BB (PDGF-BB) is well known as a
potent mitogen for smooth muscle cell proliferation. To better understand how this growth factor regulates
pulmonary arterial smooth muscle cells (PASMCs) proliferation, we sought to characterize the response to PDGF-BB
stimulation at system-wide levels, including the transcriptome and proteome.
Results: In this study, we identified 1611 mRNAs (transcriptome), 207 proteins (proteome) differentially expressed in
response to PDGF-BB stimulation in PASMCs based on RNA-sequencing and isobaric tags for relative and absolute
quantification (iTRAQ) assay. Transcription factor (TF)-target network analysis revealed that PDGF-BB regulated gene
expression potentially via TFs including HIF1A, JUN, EST1, ETS1, SMAD1, FOS, SP1, STAT1, LEF1 and CEBPB. Among
them, SMAD1-involved BMPR2/SMADs axis plays a significant role in PAH development. Interestingly, we observed
that the expression of BMPR2 was decreased in both mRNA and protein level in response to PDGF-BB. Further
study revealed that BMPR2 is the direct target of miR-376b that is up-regulated upon PDGF-BB treatment. Finally,
EdU incorporation assay showed that miR-376b promoted proliferation of PASMCs.
Conclusion: This integrated analysis of PDGF-BB-regulated transcriptome and proteome was performed for the first
time in normal PASMCs, which revealed a crosstalk between PDGF signaling and BMPR2/SMADs axis. Further study
demonstrated that PDGF-BB-induced miR-376b upregulation mediated the downregulation of BMPR2, which led to
expression change of its downstream targets and promoted proliferation of PASMCs.
Keyword: Platelet-derived growth factor-BB (PDGF-BB), Pulmonary arterial hypertension (PAH), RNA sequencing,
iTRAQ, BMPR2, miR-376b,
Background
Pulmonary arterial hypertension (PAH) is a life-threatening
disease characterized by a sustained elevation of pulmonary
arterial pressure and pulmonary vascular resistance [1, 2].
Essential pathological characteristics of PAH are excessive
proliferation and migration of pulmonary arterial smooth
muscle cells (PASMCs), leading to medial hypertrophy and
vascular remodeling [3, 4]. PASMCs are maintained in a
quiescent and non-migratory state under normal condition.
However, PASMCs proliferation and migration are signifi-
cantly promoted in response to various growth factors and
cytokines, such as platelet-derived growth factor-BB
(PDGF-BB), fibroblast growth factor, insulin-like growth
factor-1, tumor necrosis factor-α and interleukin-1 [5–7].
PDGF is the most potent mitogenic factor for vascular
smooth muscle cells (VSMCs), and exerts its actions via
binding and activating two PDGF receptor (PDGFR)
subtypes, PDGFRα and PDGFRβ [8–10]. Abundant
evidence reveals that PDGF is a major contributor to the
pathobiology of vascular disorders including PAH [11,
12]. PDGF ligands are upregulated in lung tissue and
pulmonary cells in monocrotaline (MCT)- and hypoxia-
induced experimental PAH animal [13–16]. Similar
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alterations with upregulation of PDGF ligands and
PDGFRβ were found in lung tissue and small pulmonary
arteries of patients with PAH [17, 18]. Imatinib, a PDGF
receptor antagonist, has been reported to dramatically
improve PAH in some human cases as well as animal
models, but serious side effects and drug discontinuation
are common [19, 20]. Therefore, it is particularly neces-
sary to investigate gene expression alteration globally in
PASMCs induced by PDGF-BB.
Previously, Shirvani and his colleagues have globally
determined the effect of PDGF on transcription factor
CHF1/Hey2-knockout VSMCs and demonstrate that
CHF1/Hey2 profoundly affects vascular smooth muscle
phenotype by altering both the absolute expression level
of a variety of genes and the kinetics of growth factor-
induced gene expression. [21]. In another report, Lee et
al. have analyzed the gene expression profile with mul-
tiple whole-genome expression array datasets and identi-
fied NFAT family members and target genes as
important effectors of VSMCs in response to PDGF
[22]. These studies were mainly based on traditional
high throughput technology, such as microarray, which
covered only portion of the whole genome [21, 22]. In
addition, a recent study has integrated proteomic and
transcriptomic profiles and identified a novel PDGF-
MYC network in bladder smooth muscle cells [23], how-
ever, this kind of analysis in PASMCs is still lacking.
To better understand how PDGF-BB regulates gene
expression in PASMCs, we performed the integrated
analysis of transcriptome and proteome changes in
response to PDGF-BB stimulation in rat PASMCs
(RPASMCs), based on next generation sequencing and
relative and absolute quantification (iTRAQ) technology.
Our analysis revealed a significant role of SMAD1 in
PDGF-BB induced gene expression. Further study
demonstrated that PDGF-BB-induced miR-376b upregu-
lation mediated the downregulation of BMPR2, which
led to expression change of SMAD1 targets and
promoted proliferation of PASMCs.
Results
Profiling of mRNA expression in response to PDGF-BB
RNA deep-sequencing was carried out to identify differ-
entially expressed genes in response to PDGF-BB. Total
RNA samples for RNA-Seq analysis were obtained from
RPASMCs following PDGF-BB (30 ng/ml) exposure for
0 or 12 h (2 independently isolated biological replicates).
Every sample generated more than 90,000,000 reads after
quality control, and 50,553 mRNA transcripts were iden-
tified with 373 novel transcripts that have not been
reported in rat. By quantitative analysis, 1611 transcripts
were revealed to express differentially in response to
PDGF-BB (Q value < 0.05; FPKM > 0.5; fold change
(FC) ≥ 2), with 814 up- and 797 down-regulated (Fig. 1a
and Additional file 1).
Next, gene ontology (GO) analysis was performed with
KOBAS 2.0 online software (http://kobas.cbi.pku.edu.cn/
) [24]. Results showed that these differentially expressed
genes were enriched significantly in GO terms involved
in cell proliferation, such as cell cycle, DNA replication
and cell division (Fig. 1c and Additional file 2), suggest-
ing the significant role of PDGF-BB in smooth muscle
cell proliferation as reported previously [23]. KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathway
analysis suggested that differentially expressed genes
were enriched significantly in cell cycle, DNA
replication, PI3K-Akt signaling pathway, HIF-1 signaling
pathway, focal adhesion. All of these pathways are
functionally involved in cell proliferation and migration
(Fig. 1b and Additional file 2). To find out the potential
transcription factors (TFs) mediating PDGF-BB regula-
tion on these differentially expressed mRNA, TF-targets
data were collected from TRED database [25] and
compared to differentially expressed mRNAs. Data ana-
lysis revealed that E2F4, HIFA, JUN, TP53, ATF, ESR1,
EST1, ETS1, SMAD1 and NFKB1 were top 10 TFs in
response to PDGF-BB stimulation (Fig. 1d), partly
consistent with previous reports on bladder smooth
muscle cells [23]. Interestingly, we identified as the first
time that SMAD1, an essential TF in BMPR2/SMADs
signaling pathway was regulated by PDGF-BB (Fig. 1d),
implying a potential link between BMPR2/SMADs
signaling and PDGF-BB stimulation.
Profiling of protein expression in response to PDGF-BB
iTRAQ-based proteomics analysis was performed in
RPASMCs treated with PDGF-BB in three time points
(0, 12, 24 h, duplicate per time point). Totally, 3666 pro-
teins were identified from 26,878 peptides matched with
82,825 spectra at a FDR (false discovery rate) of 5 %,
2934 of which matched to two or more peptides. Among
them, 207 proteins were differentially expressed in re-
sponse to PDGF-BB stimulation for 12 or 24 h (p < 0.05,
FC > 1.6), with 96 up- and 111 down-regulated (Fig. 2a
and Additional files 3 and 4).
GO analysis suggested the differentially expressed
protein were also enriched in GO terms involved in pro-
liferation and migration, such as focal adhesion, stress
fiber and wound healing (Fig. 2b). In KEGG pathway
analysis, only one pathway was showed to be enriched
significantly. However, among the 10 most enriched
pathways, focal adhesion and regulation of actin
cytoskeleton were involved tightly in migration and
proliferation (Fig. 2c). TF-target analysis suggested that
differentially expressed proteins majorly enriched in the
TFs including MYC, HIFA, USF, JUN and REL (Fig. 2d).
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Interestingly, differentially expressed proteins were
enriched significantly in SMAD1 as in mRNA level
(Fig. 2d).
Comparison and integration of transcriptome and
proteome
To further identify PDGF-BB mediated gene expression,
the datasets from RNA-seq and iTRAQ were applied for
the integrated analysis. Totally, 56 genes were found to
be differentially expressed at both mRNA and protein
levels (Fig. 3a). The correlation analysis suggested that
these genes expressed in high correlation in the two
levels (r = 0.87032, p < 0.001, Fig. 3b). In addition, The
integrated analysis of TFs-target suggested that differen-
tially expressed genes enriched significantly in HIF1A,
JUN, EST1, ETS1, SMAD1, FOS, SP1, STAT1, LEF1 and
CEBPB, at both mRNA and proteins levels (Fig. 3c). It is
well known that BMPR2/SMAD1 axis plays critical role
during the PAH initiation and development [26, 27].
Hence we chose potential targets of SMADs for further
analysis. KEGG pathway analysis suggested that these
differentially expressed targets enriched significantly in
PI3K-Akt signaling pathway, focal adhesion and cell
cycle, and all these pathways play significant roles in cell
proliferation and migration (Fig. 3d).
Validation of differentially expressed mRNA identified via
RNA-sequencing
Our interest focused on the proliferation, migration and
differentiation of PASMCs, hence those differentially
Fig. 1 Transcriptome analysis of RPASMCs treated with PDGF-BB. a, RNA sequencing heatmap showing a subset of genes differentially expressed
upon RPASMCs treated with PDGF-BB for 12 h (FC > 2, FKPM > 0.5 and Qvalue < 0.05 was shown); b, Gene ontology (GO) analysis was carried out
on genes differentially expressed, heatmap showing total expression of genes in the most enriched GO terms; c, the most enriched pathways of
differentially expressed genes, analyzing via KEGG pathway; d, The network was constructed with genes differentially expressed and their potential
corresponded transcription factors (TFs), showing the 15 most enriched TFs (yellow), Color of line represented the enrichment level. As to a GO or
KEGG term, Rich factor = (number of differentially expressed gene) / (total gene number), Qvalue is p-value adjusted by method “Benjamini
and Hochberg”
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expressed targets of SMADs involved in these processes
were chosen for validation via qRT-PCR (Fig. 4a). The re-
sults showed that, bambi, edn1 and id2 presented time--
dependent downregulation in response to PDGF-BB
treatment. On the other hand, myc, cdkn1a, jun, col2,
tgfb1, gja1, col5a1 and ctnnb1 displayed time-dependent
upregulation in response to PDGF-BB treatment. The
results from qRT-PCR assays were consistent with RNA-
sequencing data, except for myc (Fig. 4b).
Taken all results above together, we revealed a signifi-
cant role of SMAD1 in regulating PDGF-BB induced
gene expression. Next we would try to explore how
PDGF-BB impacts SMAD1 to regulate the correspond-
ing gene expression.
Fig. 2 Protenome analysis of RPASMCs treated with PDGF-BB. a, heatmap displaying a subset of proteins differentially expressed upon RPASMCs treated
12 or 24 h with PDGF-BB (FC > 1.6, p <0.05), measured via iTRAQ; b, GO analysis showing the most enriched GO term on differentially expressed proteins
in response to PDGF-BB; c, the most enriched pathway of proteins differentially expressed, analyzing via KEGG pathway; d, The network was constructed
with differentially expressed proteins and their potential corresponded transcription factors (TFs), displaying the 14 significantly enriched TFs (yellow), Color
of line represented the enrichment level. As to a GO or KEGG term, Rich factor = (number of differentially expressed gene) / (total gene number), Qvalue is
p-value adjusted by method “Benjamini and Hochberg”
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Downregulation of BMPR2 led to expression alteration of
SMADs targets
To explore what accounted for SMAD1-involved gene
expression in PDGF-BB stimulated RPASMCs, data from
RNA-sequencing and iTRAQ assay were analyzed and
BMPR2 was found to be downregulated in response to
PDGF-BB treatment both in mRNA and protein levels. As
well known, BMPR2 is the core upstream regulator in
BMPR2/SMADs signaling. Through BMRP2-dependent
BMRP1 activation, SMAD1 translocates into nucleus and
interacts with other transcription factors to regulate gene
expression, negatively or positively [28]. Western blot
confirmed that BMPR2 protein downregulated in re-
sponse to PDGF-BB with time-dependent manner in
RPASMCs (Fig. 4c). qRT-PCR also validated that BMPR2
mRNA altered with time- and dose- dependent manner in
response to PDGF-BB in RPASMCs (Fig. 4d, e). Taken
together, theses data suggested that PDGF-BB induced
BMPR2 downregulation could be causative of expression
alteration of SMADs targets.
miR-376b mediated the downregulation of BMPR2
To determine if PDGF-BB regulates BMPR2 expression
in post-transcriptional level, we next explored whether
Fig. 3 Comparison and integration of differential transcriptome and proteome. a, Venn diagram revealing 56 genes expressed differentially in
both mRNA and protein levels; b, Differential expression of these 56 genes was significantly correlated (r = 0.87032, p < 0.001, with Pearson test);
c, Integration of TF-target network at proteome and transcriptome levels, Color of line represented the enrichment level; d, the most enriched
pathway of differentially expressed genes corresponding to SMAD family, analyzing via KEGG pathway. As to a KEGG term, Rich factor = (number
of differentially expressed gene) / (total gene number), Q value is p-value adjusted by method “Benjamini and Hochberg”
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miRNAs involved in downregulation of BMPR2. Our lab
has investigated the expression profiling of 1078 miR-
NAs and identified a group of miRNAs differentially
expressing in HPASMCs treated by PDGF-BB [28].
Among them, 13 miRNAs were significantly changed in
both human and rat PASMCs, with 7 (miR-221-5p,
miR-221-3p, miR-376a, miR-376b, miR-146b, miR-7-5p,
miR-210) upregulated and 6 (miR-339, miR-98, miR-107,
miR-328a, miR-1281, miR-323a) downregulated in
response to PDGF-BB (Additional file 5). Further study
suggested that expression of these 13 miRNAs also
changed with time-dependent manner following PDGF-
BB treatment in RPASMCs (Fig. 5a).
Using online prediction tool of Targetscan (http://
www.targetscan.org/), multiple binding sites of miR-7,
miR-24 and miR-376b respectively were identified in
BMPR2 3’UTR. To test whether BMPR2 is a direct
target of these 3 miRNAs, the effect of miRNA mimic
on BMPR2 protein level was detected firstly. Western
blot showed that only miR-376b mimic could inhibit
BMPR2 protein level (Fig. 5b). In addition, HEK-293
cells that co-transfected with miR-376b mimic and a lu-
ciferase construct containing sequence of BMPR2 3’UTR
resulted in significant decrease in luciferase activity
(Fig. 5d), but not miR-7 and miR-24 (data not showed).
Two potential miR-376b binding sites within BMPR2
3’UTR have been identified via Targetscan (Fig. 5c),
however, they exhibited great difference in their suscep-
tibility to miR-376b mediated repression. Mutation on
the first binding site (Mut1) completely abolished the
inhibitory effect caused by miR-376b, but not the second
binding site mutated (Mut2) (Fig. 5d). Together, these
data demonstrated that upregulation of miR-376b in
response to PDGF-BB repressed the BMPR2 protein
level post-transcriptionally.
miR-376b promoted proliferation of RPASMCs
A series of reports have suggested that downregulation
of BMPR2 promoted proliferation of PASMCs [4].
Therefore, we investigated whether miR-376b could im-
pact proliferation of RPASMCs. EdU incorporation assay
showed that, miR-376b mimic significantly promoted
Fig. 4 Differential expression of SMAD family TFs in response to PDGF-BB was due to downregulation of BMPR2. a, differentially expressed genes
corresponding to SMAD involved in 3 major cellular procedures; b, q-PCR validated the expression of part of SMAD family targets, which were
identified to express differentially in response to PDGF-BB via RNA-sequencing; BMPR2 was detected in RAPSMCs treated with PDGF-BB (time
course and dose course) via Western blot at protein level c and qRT-PCR at mRNA level d, e, n = 3, *p < 0.05, **p < 0.01 vs 0 h or 0 ng/ml
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proliferation of RPASMCs (Fig. 6a, b). This data further
demonstrated that miR-376b could inhibit BMPR2
expression and promote proliferation of RPASMCs.
In summary, this study integrated transcriptome and
proteome and discovered that, in response to PDGF-BB,
miR-376b was upregulated to repress BMPR2 level.
Decreased BMPR2 further impact downstream SMADs
and altered target genes expression, which promoted
proliferation of RPASMCs (Fig. 6d).
Discussion
PDGF signaling plays important role in pulmonary vas-
cular remodeling, however, the detail mechanism under-
lying this process remains elusive. There has been a set
of genome-wide studies about PDGF-responsive gene
expression in VSMCs, which mainly based on traditional
high throughput technology, such as microarray, cover-
ing only portion of the whole transcriptome [21, 22].
Moreover, the four fundamental cellular processes,
including transcription, mRNA degradation, translation
and protein degradation, make the correlation between
mRNA and protein more complicated. Therefore, inte-
grated analysis of mRNA and protein levels would provide
more comprehensive information to understand gene
regulation [29]. However, integrating transcriptome and
proteome in VSMCs is still lacking [23]. In this study, we
utilized the next generation sequencing, combining
iTRAQ isobaric labeling technology to globally study the
gene expression regulation in PASMCs in response to
PDGF-BB. Our results confirmed the crucial role of tran-
scription factors JUN and MYC in PASMCs proliferation
and migration, as previously suggested [23]. Moreover,
our integrated analysis extended the understanding of
PDGF-BB function on PASMCs, revealing the crosstalk
between PDGF signaling and BMPR2/SMADs axis medi-
ated by miR-376b. Previous report suggested that BMP/
BMPR2/SMADs signaling prevented PDGF-BB–induced
proliferation of PASMCs by decreasing nuclear phospho-
ERK via its transcriptional target apoE [30]. Our work
suggested that PDGF signaling could regulate BMPR2/
Fig. 5 BMPR2 is a potential direct target of miR-376b. a, Heatmap showed relative level of miRNAs following PDGF-BB treatment for different time;
b, BMPR2 protein level was detected in RPASMCs transfected with miRNA mimics via Western Blot; c, The two conserved miR-376b binding sites in the
3′-UTR of BMPR2 along with the mutation sites, respectively; d, 3′-UTR luciferase reporter assay with target sites and their mutant along with miR-376b/
miR-Con mimics. Bar charts of luciferase reporter analysis represent means ± SD (n = 3), *p < 0.05, **p < 0.01 vs miR-Con/3′UTR of targets
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SMADs signaling and hence promote the proliferation of
PASMC in the other hand.
Integrated analysis indicated that PDGF-BB impacted
targets expression of 10 transcription factors, namely
HIF1A, JUN, EST1, ETS1, SMAD1, FOS, SP1, STAT1,
LEF1 and CEBPB (Fig. 3c), both in mRNA and protein
level. Mutations or downregulation of BMPR2 is pre-
sented in most cases of heritable PAH (HPAH), indicating
a functional role of BMPR2 in PAH initiation/progression
[4]. Hence we focused on exploring the effect of PDGF-
BB on BMP/BMPR2/SMADs signaling. In this study, we
identified 11 alternatively expressed genes that are poten-
tial targets of BMP/BMPR2/SMADs axis. Among them
bambi, edn1 and id2 were downregulated in a time-
dependent manner, while myc, cdkn1a, jun, col2, tgfb1,
gja1, col5a1 and ctnnb1 were upregulated (Fig. 4b). These
genes have been annotated with important roles in medi-
ating the proliferation, migration and differentiation of
PASMCs [23, 31–38], and our finding further suggested
their cooperation in mediating the PDGF-induced
dysfunction of PASMCs. For instance, since bambi
negatively regulates TGF-β-family signaling [31], bambi
downregulation and tgfb1 upregulation indicated that
PDGF signaling could positively regulate TGF-β signaling.
Previous reports showed that TGF-β signaling inhibits
PASMCs proliferation in normal condition but promotes
proliferation in BMPR2-mutated PASMCs [39]. Therefore,
activated PDGF signaling in PASMCs would lead to
increased TGF-β signaling and reduced BMP signaling,
both of which are implicated in PAH pathogenesis. HIF1A
is another TF deserved paying attention to, since many
reports have suggested the important role of HIF1A in
pulmonary vascular remodeling [26, 27]. Our analysis
revealed that, differentially expressed genes in response to
PDGF-BB were enriched the most significantly in HIF1A,
in both mRNA and protein levels (Fig. 3c). Hence, our
data indicated the tight connection between PDGF signal-
ing and hypoxia, which has received little attention [40].
Few researches have focused on the regulation of
BMPR2 expression in PASMCs. A report suggested that
miR-21 potentially suppressed BMPR2 protein level [41].
MicroRNA (miRNA) is a group of small endogenous
Fig. 6 miR-376b promoted RPASMCs proliferation. a, RPASMCs transfected with miR-376b or control mimic were incubated with EDU solution for 4 h, and
then were fixed and stained with Apollo dye (red) and DAPI (blue); b, Bar charts showing relative EdU incorporation rate in miR-376b transfected RPASMCs,
n= 3, data are shown as mean ± SD. *p< 0.05 vs control mimic; c, Bar charts showing quantification of miR-376b in transfected RPASMCs. n= 3, data are
shown as means ± SD, ***p< 0.001 vs control; d, Model depicting PDGF-BB promoted proliferation via regulating miR-376b-induced BMPR2 decrease
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noncoding single-strand RNAs (~21–25 nt), which nega-
tively regulate gene expression in translation phase [42].
miRNA has been emerged as key player in cardiovascu-
lar diseases and cancer development and progression
and, more recently, in PAH pathogenesis [42]. Several
groups has globally explored the differentially expressed
miRNAs in response to PDGF-BB in PASMCs. For
example, Brandi N. D and his colleagues cloned and
sequenced miRNAs expressed in PASMCs under
vehicle- or PDGF-BB-treated conditions and found that
miR-221 was one of the few miRNAs enriched in PDGF-
BB-treated PASMCs, which served as a modulator of the
phenotypic change of PASMCs via targeting c-Kit and
p27Kip1 [43]. Li et al. colleagues performed miRNA
microarray analysis in human aortic smooth muscle cells
(SMCs) stimulated with PDGF-BB and identified miR-
638 as one of the most significantly downregulated
miRNA in human VSMCs in response to PDGF-BB
stimulation [7]. Together, these data highlighted the
contribution of the miRNA regulation in PDGF signaling
pathway. Our lab utilized an improved miRNA detection
assay, S-Poly (T) plus assay, to profile the expression of
987 miRNAs and found 13 miRNAs with altered expres-
sion in HPASMCs after PDGF-BB stimulation. To inves-
tigate whether miRNAs involved in PDGF-BB induced
BMPR2 downregulation, online software Targetscan
were used to predict the binding sites of those 13
miRNAs, 3 of which possessed the potential binding
sites in the 3’UTR of BMPR2. However, Western blot
showed that only miR-376b mimic could inhibit the
expression of BMPR2 protein.
Our data suggested that PDGF-BB treatment induced
downregulation of BMPR2 not only at protein level but
also at mRNA level. miR-376b could inhibit the expres-
sion of BMPR2 at protein level (Fig. 5b), however,
BMPR2 mRNA in PASMCs remained unchanged after
miR-376b mimic transfection (data not shown), suggest-
ing the inhibitory effect of miR-376b on BMPR2 is post-
transcriptional. As to the transcriptional regulation of
BMPR2 expression, previous study showed that BMPR2
transcription could be affected by methylation and
acetylation in endothelial cells [44]. However, it appeared
not the case in PASMC upon PDGF stimulation, as
suppressed methylation with 5-Azacytidine and deacety-
lation with Trichostatin A failed to recover the BMPR2
mRNA levels inhibited by PDGF-BB (data not shown).
Therefore, we hypothesize that PDGF-BB regulates
BMPR2 transcription through impacting promoter
activity and further investigation is needed to verify this
hypothesis.
Conclusion
In conclusion, our results provided the first systems-level
integrated analysis of PDGF-BB-regulated transcriptome,
proteome and miRNAome (3-omics) in PASMCs. The
results demonstrated that PDGF-BB-induced miR-376b
upregulation mediated BMPR2 downregulation, which led




All experiments were carried out according to China
Council on Animal Care and the protocols used were
approved by the Animal Care and Use Committee of
Guangdong Province, China.
Cell culture and transfection
RPASMCs were generous gifts from Dr. Zeng Yan, and
cultured as previously reported [45]. Cultured primary
RPASMCs (≤4 passage) were starved for 12 h (h) and then
treated with PDGF-BB (30 ng/ml, R&D system, Minneap-
olis, MN) for different time (0, 2, 4, 6, 12, 24 h). miRNA
mimics (20nM) were transfected with K2 transfection
reagent (Biontex, Planegg, Germany) in RPASMCs. HEK-
293a, a cell line derived from human embryonic kidney,
was purchased from American Type Culture Collection
(Manassas, USA). The transfection of miRNA mimic and
DNA plasmids into HEK-293 cells were performed with
polyethylenimine (PEI, Geneups, Shenzhen, China).
RNA deep-sequencing and identification of differentially
expressed mRNA
Total RNAs were extracted with RNAiso Plus (Takara
biotechnology Co., Dalian, China). Following procedure
was performed by the sequencing company (Novogene
Bioinformatics Technology Co., Beijing, China). Briefly,
Sequencing libraries were generated using the rRNA-
depleted RNAbyNEBNext® Ultra™ Directional RNA
Library Prep Kit for Illumina® (NEB, USA) following
manufacturer’s recommendations. The libraries were
sequenced on an Illumina Hiseq 2000 platform and
100 bp paired-end reads were generated. Demultiplexed
and quality filtered reads were then aligned to Rat refer-
ence assembly (Rn5) using TopHat (v.2.0.9) [46]. The
mapped reads of each sample were assembled by both
Scripture (beta2) [47] and Cufflinks (v2.1.1) [48] in a
reference-based approach.
Cuffdiff (v2.1.1) was used to calculate FPKMs (frag-
ments per kilo-base of exon per million fragments
mapped) of coding genes in each sample [48]. Gene
FPKMs were computed by summing the FPKMs of
transcripts in each gene group. Cuffdiff provides statis-
tical routines for determining differential expression in
digital transcript or gene expression data using a model
based on the negative binomial distribution [48]. Genes
with a Q value < 0.05, FKPRM > 0.5 and FC > 2 were
assigned as differentially expressed.
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GO and KEGG analysis
GO-term analysis was utilized to determine the potential
functions of differentially expressed genes in response to
PDGF-BB. GO term with Q-values ≤ 0.05 was considered
to be significantly enriched. Meanwhile, KEGG analysis
was used to assess the pathway that differential genes
may involve in. KEGG term with Q-values ≤ 0.05 was
considered to be significantly enriched. Both GO and
KEGG analysis were performed with KOBAS 2.0 online
software (http://kobas.cbi.pku.edu.cn/) [24].
Identification of key transcription factors (TFs) regulating
differentially expressed genes
To identify key TFs, TF-target interaction data for 179
TFs were collected from public database TRED to build
a expanded list of rat TF-target interaction, which
includes homologous human and mouse ones [25]. We
utilized the enrichment level to valuate the significance
of TFs in PDGF-BB regulating gene expression, which
was assessed with Fisher’s exact test, and the FDR
correction method is “Benjamini and Hochberg”.
iTRAQ labeling and Identification of differentially
expressed proteins
ITRAQ labeling was performed using the 8-plex iTRAQ
reagents (Applied Biosystems, Foster City, CA, USA) as
previously reported [49]. Then, the labeled samples were
lyophilized and assigned to HPLC-MS/MS (high
performance liquid chromatography-mass spectrometry/
mass spectrometry) analysis in HPLC electrospray
ionization MS/MS system (Applied Biosystems, Foster
City, CA, USA).
Quality assessment of the iTRAQ datasets was
performed as described [49]. The statistical differences
between two groups were assessed with the double-sided
Student’s t test. Additionally, fold-change = average (12
or 24 h) / average (0 h). The differentially expressed
proteins were identified using the following criteria: 1)
overall P values are less than 0.05; 2) proteins quantified
in at least two replicates; and 3) absolute fold changes
are larger than 1.6.
Quantitative RT-PCR
For mRNA detection, total RNA was reversely tran-
scribed using M-MLV Reverse Transcriptase (TaKaRa,
Dalian, China) with oligo(dT)18 plus random hexamer
primers (Promega, Madison, WI). qRT-PCR was per-
formed with gene specific primers and SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA) on
ABI StepOne real-time PCR System (Applied Biosys-
tems, Foster City, CA, USA). The expression level of
each gene was normalized to internal control β-actin
gene and the expression level of each mRNA was
calculated using the 2(−ΔΔCT) method. The S-Poly(T)
Plus method was used for miRNA detection as previ-
ously reported [50]. The snoRNA-202 was used as an
internal control. Primers used for reverse transcription
and qRT-PCR were summarized in Additional file 6.
Western blot
Cells were lysed with ice-cold RIPA (50 mM Tris–HCl,
pH 7.5; 150 mM NaCl; 1 % NP-40; 0.25%sodium deoxy-
cholate, 1 mM EDTA) buffer supplemented with prote-
ase inhibitor cocktail (Sigma-Aldrich Inc., St. Louis,
MO). Each sample with 30 μg protein were then electro-
phoresed on the sodium dodecyl sulfate (SDS) polyacryl-
amide gel and then electroblotted to nitrocellulose filter
membranes (Millipore, Bedford, MA). Membranes were
immersed in blocking buffer (5 % degreased milk powder)
for 1 h and incubated with antibodies against BMPR2
(ProteinTech Group, Chicago, IL), β-actin (SantaCruz
Biotechnology, Santa Cruz, CA) overnight at 4 °C. Next,
the membranes were washed and incubated with horse-
radish peroxidase-conjugated secondary antibodies
(Jackson Immuno-Research, West Grove, PA) for 1 h at
room temperature. The protein bands were visualized
with the SuperSignal chemiluminescent detection module
(Pierce, Thermo Scientific Inc., San Jose, CA).
3′UTR luciferase reporter assay
TargetScan algorithm (http://www.targetscan.org) was ap-
plied to predict targets and the miRNA binding sites. The
3′UTR of BMPR2 were PCR amplified and inserted into
pGL4-plasmid (Promega). The corresponding mutant con-
structs with six mutated residues in the region of seeding
sequence were generated by site-directed mutagenesis. Lu-
ciferase activity was measured in cell extracts with a Lumat
LB9508 luminometer (Berthold, Bad Wildbad, Germany).
The primers used were as follow: cloning 3′ UTR of
BMPR2: 5- GGA ATT CCC CGC CTT GTT ATC AGT
CG-3 (forward) and 5- CCG CTC GAG TTA CAG CAA
GCC TTT TAA ACC T −3 (reverse); BMPR2-mut1,
5-GAT GCC AGA TAC TAC GCT GAC ATT AAG CCA
CTG A-3 (forward) and 5-TCA GCG TAG TAT CTG
GCA TCC ATA GAT AAT ACA AAA G-3 (reverse);
BMPR2-mut2, 5- GAA GAG TTT AGA TAC TAT AAG
TGT AAG TAA ATG CTT TG-3 (forward) and 5- TAC
ACT TAT AGT ATC TAA ACT CTT CAG TGG CTT
AAT G −3 (reverse).
Proliferation measurement (EdU incorporation assay)
EdU labeling was performed using the EdU Assay Kit
(Ribobio, Guangzhou, China) as recommended by the
manufacturer. Briefly, approximately 1 × 104 cells were
seeded intriplicate in 48-well plates, and the cells were
cultured for 24 h and then transfected with miR-376b or
control mimic for 48 h, then exposed to 20 μM EdU for
4 h at 37 °C. The cells were then fixed in 4 %
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paraformaldehyde for 30 min at room temperature and
permeabilized in 0.5 % Triton X-100 for 10 min. Cells
were washed with PBS, and each well was incubated with
200 μl 1 × Apollo® reaction cocktail for 30 min. DNA was
then stained with 1 μg/ml DAPI (200 μl per well) for
30 min and imaged under a fluorescent microscope. All
data are shown as a percentage of control mimic.
Statistical analysis
Except for those omics data, all data shown are mean
values of at least three experiments with standard devi-
ation (SD). Correlation test was performed with Pearson
method. When only two groups were compared, the
statistical differences were assessed with the double-
sided Student’s t test. Significant differences between
groups were analyzed using one-way ANOVA. A p value
less than 0.05 was considered significant.
Additional files
Additional file 1: Table S1. Differentially expressed mRNA in RPASMCs
treated with PDGF-BB for 12 h. (XLSX 185 kb)
Additional file 2: GO and KEGG analysis for differentially expressed
mRNA. (XLSX 956 kb)
Additional file 3: Table S2. Differentially expressed protein in RPASMCs
treated with PDGF-BB for 12 h. (XLSX 33 kb)
Additional file 4: Table S3. Table S2. Differentially expressed protein in
RPASMCs treated with PDGF-BB for 24 h. (XLSX 42 kb)
Additional file 5: Differentially expressed miRNA in HPASMCs. (XLSX 9 kb)
Additional file 6: Primers for qRT-PCR. (XLSX 15 kb)
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